Investigating how xylazine interacts with opioid receptors
Official title: Xylazine Interaction with Opioid Receptors: Binding and Signaling
Funded at University of Rochester · NIH-11139226 · Data updated 2026-11-12
This study is looking at how xylazine, a drug not meant for people, interacts with the body's opioid receptors to see if it makes other drugs stronger, which could help find better ways to support those dealing with substance use issues.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | May 1, 2025 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $231,000 |
| NIH project number | 1R21DA061044-01A1 |
| Project ID | NIH-11139226 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who have experienced adverse effects from xylazine or are involved in substance use that includes xylazine.
✕Less likely to help
Patients who do not use xylazine or are not affected by its interactions with opioids may not benefit from this research.
What this research studies
This research aims to explore the effects of xylazine, a drug not approved for human use, on opioid receptors in the body. The study will assess whether xylazine and its metabolites act as agonists or modulators at specific opioid receptors, which could help understand its role in enhancing the effects of other illegal drugs. By examining the binding and signaling properties of xylazine, researchers hope to uncover important pharmacological insights that could inform treatment strategies for patients affected by substance use. The methodology includes laboratory experiments using cell cultures to measure receptor interactions and activity.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and management of xylazine's effects, potentially improving treatment options for patients with substance use disorders.
How similar studies have gone: While research on xylazine is limited, studies on similar compounds have shown promising results in understanding their interactions with opioid receptors.
Where this research is happening
-
University of Rochester
Rochester, United States Active
Researchers
- Principal investigator: Bidlack, Jean M — University of Rochester
- Study coordinator: Bidlack, Jean M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.